A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients With Osteoarthritis of the Hip
NCT ID: NCT00131326
Last Updated: 2017-07-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
INTERVENTIONAL
2003-11-30
2006-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
6-month Efficacy and Safety of Synolis VA 80/160 in Hip Osteoarthritis
NCT05829733
The MONOVISC Hip Osteoarthritis Study
NCT02698865
Synvisc-One for Younger, Active Patients With Osteoarthritis
NCT01625013
A Prospective Clinical Study On A Total Hip Resurfacing System
NCT00604734
Optimization of Synvisc-One for Knee OA
NCT02029703
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Synvisc (hylan G-F 20)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
35 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genzyme, a Sanofi Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Genzyme Corporation
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Genzyme, a Sanofi Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Alabama Clinical Therapeutics
Birmingham, Alabama, United States
John Higginbotham, MD Sports Medicine
Huntsville, Alabama, United States
Affiliated Orthopedic Specialists
Scottsdale, Arizona, United States
Arkansas Orthopaedic Specialists
Little Rock, Arkansas, United States
Cedars-Sinai Orthopedic Center
Los Angeles, California, United States
Jackson Arthritis Center
Oakland, California, United States
Orthopedic Medical Group
San Diego, California, United States
Orthopedic Specialists of Tamp Bay, P.A.
Clearwater, Florida, United States
Orthopedic Institute at Mercy Hospital
Miami, Florida, United States
Hughston Sports Medicine Foundation
Columbus, Georgia, United States
Idaho Arthritis & Osteoporosis Center
Meridian, Idaho, United States
Northwestern Orthopaedic Institute
Chicago, Illinois, United States
Illinois Bone and Joint Institute, Ltd.
Morton Grove, Illinois, United States
David S. Tearse, MD (Private Practice)
Cedar Rapids, Iowa, United States
Kansas City Orthopedic Institute
Leawood, Kansas, United States
Bluegrass Orthopaedics
Lexington, Kentucky, United States
Orthopedic Specialists of Louisiana
Shreveport, Louisiana, United States
Maryland General Hospital
Baltimore, Maryland, United States
Family Orthopedic Associates
Flint, Michigan, United States
Washington University School of Medicine
St Louis, Missouri, United States
UMDNJ-RWJ University Orthopedic Group
New Brunswick, New Jersey, United States
Hospital for Special Surgery
New York, New York, United States
Health Research Institute
Oklahoma City, Oklahoma, United States
Orthopedic Center for Joint Replacement & Sports Medicine
Grants Pass, Oregon, United States
Altoona Center for Clinical Research
Duncansville, Pennsylvania, United States
Lancaster Orthopedic Group
Lancaster, Pennsylvania, United States
Allegheny Orthopedic Associates
Pittsburgh, Pennsylvania, United States
Conway Medical Center
Conway, South Carolina, United States
Chattanooga Center for Sports
Chattanooga, Tennessee, United States
Gurdev Gill, MD (Private Practice)
Lubbock, Texas, United States
Carilion Bone and Joint Center, Vinton Orthopedic Surgery
Vinton, Virginia, United States
Arthritis Northwest
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Spitzer AI, Bockow BI, Brander VA, Yates JW, MacCarter DK, Gudger GK, Haller S, Lake SL, Magilavy DB. Hylan G-F 20 improves hip osteoarthritis: a prospective, randomized study. Phys Sportsmed. 2010 Jun;38(2):35-47. doi: 10.3810/psm.2010.06.1781.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SYNV-004-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.